Feng Gao
Fujian Medical University(CN)Washington University in St. Louis(US)Harbin Institute of Technology(CN)Sichuan University(CN)China Rehabilitation Research Center(CN)Chinese PLA General Hospital(CN)Chinese General Hospital College of Nursing and Liberal Arts(PH)Chinese Academy of Engineering(CN)West China Hospital of Sichuan University(CN)Tsinghua Sichuan Energy Internet Research Institute(CN)307th Hospital of Chinese People’s Liberation Army(CN)Linyi People's Hospital(CN)Jinan Central Hospital(CN)Weifang People's Hospital(CN)Children's Hospital of Zhejiang University(CN)Gansu Provincial Hospital(CN)First Affiliated Hospital of Fujian Medical University(CN)The Military General Hospital of Beijing PLA(CN)Jiangsu Cancer Hospital(CN)Zhejiang Provincial People's Hospital(CN)Huanghuai University(CN)The 309th Hospital of Chinese People's Liberation Army(CN)Shandong First Medical University(CN)First Affiliated Hospital Zhejiang University(CN)Inner Mongolia Medical University(CN)Northeast Forestry University(CN)Saint Louis University(US)Southwest Jiaotong University(CN)Shaanxi University of Chinese Medicine(CN)Beijing Sport University(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Epigenetics and DNA Methylation, Histone Deacetylase Inhibitors Research, Pancreatic and Hepatic Oncology Research, Hematopoietic Stem Cell Transplantation
Most-Cited Works
- → Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer(2014)577 cited
- → Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey(2010)544 cited
- → In Vivo Molecular Photoacoustic Tomography of Melanomas Targeted by Bioconjugated Gold Nanocages(2010)460 cited
- → Higher Than Normal Plasma Interleukin-6 Concentrations in Cancer Patients With Depression: Preliminary Findings(2001)442 cited
- → An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies(2018)385 cited
- → NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer(2017)371 cited